GLP-1 news and data changes
Last updated
Everything that changed in the data on this site, written from each source's own record and linked to it.
Latest change . RSS feed
5,207 changes on record, the newest 120 FDA actions and label updates listed here: 181 FDA actions and label updates, 11 generic challenges and patent listings, 2 Medicare and Medicaid data releases, 2,143 cash price updates, 2,595 seller record updates, 68 recalls, 115 trial updates, 45 published studies, 47 reviews by us. In the last 7 days, 877 changes were at a source (a seller's price or terms, FDA, a label, a trial, a study) and 1,000 were sellers and facts we added, shown one line per seller. The sources are compared with the day before every day at 14:07 UTC, and each line is written from the source's own record.
Nov 9, 2026
- FDAMedWatch Alert: FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition: FDA Safety Communication (fda.gov/safety/medical-product-safety-information/medwatch-alert-fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras)
Nov 3, 2026
- FDAFDA posted a warning letter to RonanRx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026)
- FDAFDA posted a warning letter to RonanRx, Inc. dba RonanRx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026)
Oct 30, 2026
- FDA labelFDA label updated: Liraglutide (Lupin Pharmaceuticals, Inc.), effective 2026-10-30 (api.fda.gov/drug/label.json)
Oct 28, 2026
- FDAFDA's adverse event reports were updated, and each brand's report counts with them (fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard)
Oct 15, 2026
- FDA labelFDA label updated: liraglutide (Orbicular Pharmaceutical Technologies Private Limited), effective 2026-10-15 (api.fda.gov/drug/label.json)
- FDA labelFDA label updated: Liraglutide (Orbicular Pharmaceutical Technologies Private Limited), effective 2026-10-15 (api.fda.gov/drug/label.json)
Oct 9, 2026
- FDA labelFDA label updated: Liraglutide (Cipla USA Inc.), effective 2026-10-09 (api.fda.gov/drug/label.json)
Oct 6, 2026
- FDAFDA posted 2 warning letters naming a GLP-1: selling unapproved drugs online (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
Sep 22, 2026
- FDAFDA posted 2 warning letters naming a GLP-1: manufacturing or quality problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
Sep 1, 2026
- FDAFDA posted 5 warning letters naming a GLP-1: unapproved drugs (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
Aug 28, 2026
- FDA labelFDA label updated: Zepbound (Eli Lilly and Company), effective 2026-08-28 (api.fda.gov/drug/label.json)
Aug 27, 2026
- FDA labelFDA label updated: Mounjaro (Eli Lilly and Company), effective 2026-08-27 (api.fda.gov/drug/label.json)
- FDAFDA approved an efficacy supplement for Mounjaro (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved an efficacy supplement for Mounjaro (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Aug 26, 2026
- FDAFDA approved an efficacy supplement for Zepbound (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Aug 4, 2026
- FDAFDA approved a labeling supplement for Foundayo (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jul 29, 2026
- FDA labelFDA label updated: Foundayo (Eli Lilly and Company), effective 2026-07-29 (api.fda.gov/drug/label.json)
Jul 27, 2026
- FDA labelFDA label updated: Liraglutide (Meitheal Pharmaceuticals Inc.), effective 2026-07-27 (api.fda.gov/drug/label.json)
Jul 1, 2026
- FDAFDA approved a generic liraglutide from Sandoz (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jun 24, 2026
- FDA labelFDA label updated: Liraglutide (NorthStar Rx LLC), effective 2026-06-24 (api.fda.gov/drug/label.json)
Jun 18, 2026
- FDA labelFDA label updated: Wegovy (Novo Nordisk Pharmaceutical Industries, LP), effective 2026-06-18 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
- FDA labelFDA label updated: liraglutide (Cipla USA Inc.), effective 2026-06-18 (api.fda.gov/drug/label.json)
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jun 16, 2026
- FDA labelFDA label updated: Trulicity (Eli Lilly and Company), effective 2026-06-16 (api.fda.gov/drug/label.json)
- FDAFDA posted a warning letter to VivioMD: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viviomd-group-llc-dba-viviomd-728295-06082026)
- FDAFDA posted a warning letter to Momentum Health 360: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/momentum-health-360-dba-momentum-health-728286-06082026)
- FDAFDA posted a warning letter to AM Rx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-am-rx-728275-06082026)
- FDAFDA posted a warning letter to altRx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/trinity-healthcare-supply-llc-dba-altrx-728236-06082026)
- FDAFDA posted a warning letter to Maximus: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maximus-health-inc-dba-maximus-730095-06082026)
- FDAFDA posted a warning letter to OrderlyMeds: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/orderlymeds-llc-dba-orderlymeds-728291-06082026)
- FDAFDA posted 13 warning letters naming a GLP-1: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
- FDAFDA posted a warning letter to Medica Weight Loss: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medica-weight-loss-728284-06082026)
- FDAFDA posted a warning letter to Eden: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eden-health-international-inc-dba-eden-728279-06082026)
- FDAFDA posted a warning letter to Clover Meds: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/clover-meds-llc-dba-clover-meds-728234-06082026)
- FDAFDA posted a warning letter to NexLife: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nexlife-inc-dba-nexlife-730096-06082026)
- FDAFDA posted a warning letter to Mint Med: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glow-medispa-llc-dba-mint-med-730390-06082026)
- FDAFDA posted a warning letter to Fitish RX: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitish-728280-06082026)
- FDAFDA posted a warning letter to Thrivelab: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrivelab-co-dba-thrivelab-728294-06082026)
- FDAFDA posted a warning letter to Joi + Blokes: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/joi-and-blokes-dba-joi-blokes-728283-06082026)
- FDAFDA posted a warning letter to RoenRx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/roen-health-inc-dba-roenrx-728293-06082026)
- FDAFDA posted a warning letter to NativeMed: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/nativemed-llc-dba-nativemed-728287-06082026)
Jun 15, 2026
- FDAFDA approved a generic liraglutide from Mylan Institutional (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jun 2, 2026
- FDAFDA approved a labeling supplement for Saxenda (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jun 1, 2026
- FDA labelFDA label updated: Ozempic (Novo Nordisk Pharmaceutical Industries, LP), effective 2026-06-01 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
May 27, 2026
- FDA labelFDA label updated: Exenatide (Amneal Pharmaceuticals LLC), effective 2026-05-27 (api.fda.gov/drug/label.json)
May 19, 2026
- FDAFDA posted a warning letter to Harbin Jixianglong Biotech Co., Ltd.: manufacturing or quality problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/harbin-jixianglong-biotech-co-ltd-723330-05012026)
May 14, 2026
- FDA labelFDA label updated: Liraglutide (Hikma Pharmaceuticals USA Inc.), effective 2026-05-14 (api.fda.gov/drug/label.json)
May 12, 2026
- FDAFDA posted a warning letter to ProRx LLC: compounding problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026)
May 5, 2026
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
May 1, 2026
- FDAList of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal)
Apr 22, 2026
- FDAFDA approved a labeling supplement for Zepbound (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Apr 21, 2026
- FDAFDA posted a warning letter to New Life Pharma LLC: manufacturing or quality problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/new-life-pharma-llc-725661-04142026)
- FDAFDA posted a warning letter to Thrive Health and Wellness, LLC dba Thrive Health Solutions: compounding problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/thrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026)
Apr 7, 2026
- FDAFDA posted 6 warning letters naming a GLP-1: selling unapproved drugs online (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
- FDAFDA tentatively approved a generic semaglutide from Apotex, which cannot be sold yet (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Apr 1, 2026
- FDAFDA approved Foundayo (orforglipron) (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Mar 30, 2026
- FDAFDA approved a generic liraglutide from Fresenius Kabi Usa (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Mar 19, 2026
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved an efficacy supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Mar 17, 2026
- FDAFDA posted a warning letter to Apothecary Pharma, LLC: compounding problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apothecary-pharma-llc-717972-12012025)
Mar 12, 2026
- FDAFDA approved a labeling supplement for Trulicity (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Mar 11, 2026
- FDAFDA approved a generic liraglutide from Biocon Pharma (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Mar 10, 2026
- FDAFDA posted a warning letter to Novo Nordisk Inc.: other (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-717576-03052026)
Mar 5, 2026
- FDAFDA posted a warning letter to Premium Health Management Inc. dba Premium Health: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premium-health-management-inc-dba-premium-health-721474-02202026)
- FDAFDA posted a warning letter to Premium Health: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premium-health-management-inc-dba-premium-health-721474-02202026)
Mar 3, 2026
- FDAFDA posted a warning letter to Good Girl Rx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/good-girl-llc-dba-goodgirlrx-721449-02202026)
- FDAFDA posted a warning letter to MaxLife: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/maxlife-technologies-inc-dba-maxlife-721453-02202026)
- FDAFDA posted a warning letter to Pharmazee: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pharmazee-721473-02202026)
- FDAFDA posted a warning letter to MEDVi: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026)
- FDAFDA posted a warning letter to Join Josie: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/join-josie-717986-02202026)
- FDAFDA posted a warning letter to Measured: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/better-health-labs-inc-dba-measured-721454-02202026)
- FDAFDA posted a warning letter to KIN Meds: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kin-meds-721450-02202026)
- FDAFDA posted a warning letter to Genesis Health: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genesis-health-international-inc-dba-genesis-721451-02202026)
- FDAFDA posted a warning letter to Bliv: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/bliv-wellness-llc-dba-bliv-721479-02202026)
- FDAFDA posted a warning letter to NewSelf: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newself-limited-dba-newself-721472-02202026)
- FDAFDA posted a warning letter to WeightCare: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/weightless-medical-llc-dba-weightcare-721478-02202026)
- FDAFDA posted a warning letter to SkinnyRx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026)
- FDAFDA posted a warning letter to Zappy Health: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kare-solutions-llc-dba-zappy-717991-02202026)
- FDAFDA posted a warning letter to Strut Health: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/strut-health-llc-dba-strut-721448-02202026)
- FDAFDA posted a warning letter to FitRx: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fitrx-llc-dba-fitrx-717987-02202026)
- FDAFDA posted a warning letter to Zeuss: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/zeuss-llc-dba-zeuss-717985-02202026)
- FDAFDA posted a warning letter to Refills: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/refills-health-llc-dba-refills-health-721475-02202026)
- FDAFDA posted a warning letter to Newman Clinic: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/newman-clinic-pllc-dba-newman-clinic-721470-02202026)
- FDAFDA posted a warning letter to Alan Meds (Alan Health): false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alan-health-technologies-inc-dba-alan-721814-02202026)
- FDAFDA posted a warning letter to Ivim Health: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ivim-services-llc-dba-ivim-721816-02202026)
- FDAFDA posted a warning letter to Belle: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/belle-health-llc-dba-belle-721795-02202026)
- FDAFDA posted a warning letter to Fifty 410: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aspen-aesthetics-dba-fifty-410-721481-02202026)
- FDAFDA posted 20 warning letters naming a GLP-1: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters)
- FDAFDA posted a warning letter to GenoGenix LLC: compounding problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/genogenix-llc-718739-01202026)
- FDAFDA posted a warning letter to VIV RX: false or misleading claims by a telehealth seller (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/viv-health-inc-dba-viv-rx-721818-02202026)
Feb 27, 2026
- FDA labelFDA label updated: Liraglutide (Teva Pharmaceuticals, Inc.), effective 2026-02-27 (api.fda.gov/drug/label.json)
Feb 25, 2026
- FDAFDA approved a labeling supplement for Saxenda (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDA labelFDA label updated: Saxenda (Novo Nordisk Pharmaceutical Industries, LP), effective 2026-02-25 (api.fda.gov/drug/label.json)
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Zepbound (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Feb 24, 2026
- FDAFDA approved a generic liraglutide from Biocon Pharma (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a generic liraglutide from Orbicular (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Feb 10, 2026
- FDAFDA posted a warning letter to Boothwyn Pharmacy, LLC: compounding problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/boothwyn-pharmacy-llc-717525-01162026)
Jan 30, 2026
- FDA labelFDA label updated: Ozempic (Novo Nordisk Pharmaceutical Industries, LP), effective 2026-01-30 (api.fda.gov/drug/label.json)
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDA labelFDA label updated: Liraglutide (Teva Pharmaceuticals USA, Inc.), effective 2026-01-30 (api.fda.gov/drug/label.json)
Jan 29, 2026
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jan 20, 2026
- FDAFDA approved a labeling supplement for Mounjaro (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Zepbound (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Jan 14, 2026
- FDAFDA approved a generic liraglutide from Orbicular (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Dec 23, 2025
- FDAFDA posted a warning letter to Darmerica, LLC: manufacturing or quality problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025)
Dec 22, 2025
- FDAFDA approved Wegovy (semaglutide) (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Dec 19, 2025
- FDAFDA approved an efficacy supplement for Mounjaro (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Dec 2, 2025
- FDAFDA posted a warning letter to PQ Pharmacy, LLC: compounding problems (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pq-pharmacy-llc-715795-10102025)
Nov 21, 2025
- FDAFDA approved an efficacy supplement for Wegovy (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Oct 17, 2025
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved an efficacy supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
Oct 14, 2025
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)
- FDAFDA approved a labeling supplement for Ozempic (accessdata.fda.gov/scripts/cder/daf/index.cfm)